Status:
NOT_YET_RECRUITING
A Mass Balance Study of Oral [14C] ABBV-932 in Healthy Adult Male Participants
Lead Sponsor:
AbbVie
Conditions:
Healthy Volunteer
Eligibility:
MALE
18-65 years
Phase:
PHASE1
Brief Summary
The main objective of this study is to assess the safety and tolerability of ABBV-932 in healthy adult male participants.
Eligibility Criteria
Inclusion
- Body Mass Index (BMI) ≥ 18.0 to ≤ 29.9.0 kg/m\^2 after rounding to the tenths decimal. BMI is calculated as weight in kg divided by the square of height measured in meters.
- Male participant who is not considering fathering a child or donating sperm during the study and for 100 days after the study drug administration
- A condition of general good health, based upon the results of a medical history, physical exam
Exclusion
- Has not participated in another \[14C\] absorption, distribution, metabolism, excretion (ADME) study with a radiodose above 0.1 MBq in the period of 12 months prior to screening.
- Use of any medications/products known to alter drug absorption, metabolism, or excretion processes, within 30 days or within a period defined by 5 half-lives, whichever is longer, prior to study drug administration.
- Prior exposure to ABBV-932 or cariprazine within the past 90 days.
Key Trial Info
Start Date :
October 14 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2026
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT06953934
Start Date
October 14 2025
End Date
February 1 2026
Last Update
August 8 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.